Wyden and Brown Urge FTC to Investigate Emerging Anti-Competitive Practices by PBMs

As Congress and FTC Continue to Investigate and Address the Role of Pharma Middlemen in High Drug Costs, Leading Senators Highlight Concerning New Practices Known as “Co-Manufacturing”

Washington, D.C. – Senate Finance Committee Chair Ron Wyden, D-Ore., and Finance Committee Member Senator Sherrod Brown, D-Ohio, today urged the Federal Trade Commission (FTC) to expand its work into additional anti-competitive practices by pharmacy benefit managers (PBMs) that the industry may be using to put up barriers to competition and take in larger revenues.

Read the full release >